250122-41-9

Upstream product

• 250122-38-4 (2R,4R)-4-benzyloxypyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester 2-methyl ester 
• 250122-39-5 tert-butyl (2R,4R)-4-(benzyloxy)-2-formylpyrrolidine-1-carboxylate 
• 2584-71-6 cis-hydroxy-D-proline 
• 114676-47-0 (2R,4R)-4-Hydroxy-pyrrolidine-2-carboxylic acid methyl ester 
• 114676-69-6 (2R,4R)-1-tert-butyl 2-methyl 4-hydroxypyrrolidine-1,2-dicarboxylate 
• 24424-99-5 di-tert-butyl dicarbonate 

Downstream Products

• 250122-46-4 4-(benzylamino-methyl)-2-(5-imidazol-1-yl-1H-indol-3-ylmethyl)-pyrrolidine-1-carboxylic acid tert-butyl ester 
• 250122-43-1 4-benzyloxy-2-(5-imidazol-1-yl-1H-indol-3-ylmethyl)-pyrrolidine-1-carboxylic acid tert-butyl ester 
• 250122-42-0 3-((2S,4R)-4-Benzyloxy-pyrrolidin-2-ylmethyl)-5-imidazol-1-yl-1H-indole 

Relevant academic research and scientific papers

2,7-Diazabicyclo[3.3.0]octanes as novel h5-HT(1D) receptor agonists

The conformational restriction of a (benzylamino)methyl substituted pyrrolidine to form 2,7-diazabicyclo[3.3.0]octanes has led to a series of compounds with high affinity at the h5-HT(1D) receptor as well as dramatically increased concentrations in the hepatic portal vein following oral administration.